All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C336 | Human anti-VP22 T cell receptor (CB-C076), pCDTCR1 | HSV-2 | CB-C076 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C337 | Human anti-VP22 T cell receptor (CB-C077), pCDTCR1 | HSV-2 | CB-C077 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C338 | Human anti-VP22 T cell receptor (CB-C078), pCDTCR1 | HSV-2 | CB-C078 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C339 | Human anti-VP22 T cell receptor (CB-C079), pCDTCR1 | HSV-2 | CB-C079 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C340 | Human anti-VP22 T cell receptor (CB-C080), pCDTCR1 | HSV-2 | CB-C080 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C341 | Human anti-VP22 T cell receptor (CB-C081), pCDTCR1 | HSV-2 | CB-C081 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C342 | Human anti-VP22 T cell receptor (CB-C082), pCDTCR1 | HSV-2 | CB-C082 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C343 | Human anti-VP22 T cell receptor (CB-C083), pCDTCR1 | HSV-2 | CB-C083 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C344 | Human anti-VP22 T cell receptor (CB-C084), pCDTCR1 | HSV-2 | CB-C084 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C364 | Human anti-VP22 T cell receptor (CB-C104), pCDTCR1 | HSV-2 | CB-C104 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C365 | Human anti-VP22 T cell receptor (CB-C105), pCDTCR1 | HSV-2 | CB-C105 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C366 | Human anti-VP22 T cell receptor (CB-C106), pCDTCR1 | HSV-2 | CB-C106 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C367 | Human anti-VP22 T cell receptor (CB-C107), pCDTCR1 | HSV-2 | CB-C107 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C368 | Human anti-VP22 T cell receptor (CB-C108), pCDTCR1 | HSV-2 | CB-C108 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C369 | Human anti-VP22 T cell receptor (CB-C109), pCDTCR1 | HSV-2 | CB-C109 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C370 | Human anti-VP22 T cell receptor (CB-C110), pCDTCR1 | HSV-2 | CB-C110 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C371 | Human anti-VP22 T cell receptor (CB-C111), pCDTCR1 | HSV-2 | CB-C111 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C372 | Human anti-VP22 T cell receptor (CB-C112), pCDTCR1 | HSV-2 | CB-C112 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C373 | Human anti-VP22 T cell receptor (CB-C113), pCDTCR1 | HSV-2 | CB-C113 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-C374 | Human anti-VP22 T cell receptor (CB-C114), pCDTCR1 | HSV-2 | CB-C114 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION